NCT04737122 is a Phase 1 clinical trial of LM-061 in Advanced Tumours, sponsored by LaNova Medicines Limited.

Who is sponsoring NCT04737122?

NCT04737122 is sponsored by LaNova Medicines Limited.

What drugs are being tested in NCT04737122?

Interventions in NCT04737122: LM-061, Toripalimab.

What condition does NCT04737122 study?

NCT04737122 studies Advanced Tumours.

Is NCT04737122 still recruiting?

NCT04737122 is currently terminated. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT04737122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of LM-061 in Subjects in Advanced Tumors

Terminated Phase 1 Last updated 10 October 2023

What this trial tests

Phase 1 trial testing LM-061 in Advanced Tumours in 18 participants. Terminated before completion.

Timeline

6 May 2021

Primary endpoint
19 July 2022

1 December 2022

Quick facts

Lead sponsor	LaNova Medicines Limited
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	6 May 2021
Primary completion	19 July 2022
Estimated completion	1 December 2022
Sites	1 location across Australia

Drugs / interventions tested

LM-061 — full drug profile →
Toripalimab (TORIPALIMAB) — full drug profile →

Conditions studied

Advanced Tumours — all drugs for Advanced Tumours →

Sponsor

LaNova Medicines Limited — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Tumours. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase I, open-label, dose escalation study to evaluate the safety, tolerability, PK, and preliminary efficacy of LM-061 in subjects with advanced tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of LM-061

Trials testing the same drug.

NCT04882176 — A Clinical Study Preliminary Efficacy of LM-061 Tablet in Subjects With Advanced Tumours · Phase 1, PHASE2 · terminated

Other LaNova Medicines Limited trials

Trials by the same sponsor.

NCT07362186 — LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gast · Phase 3 · not yet recruiting
NCT07387081 — Phase II Study of LM-24C5 · Phase 2 · recruiting
NCT06682780 — A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07112222 — A Study of LM-350 in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06868199 — A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04737122 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LaNova Medicines Limited
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04737122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing